Neoplasm News and Research

RSS

Neoplasm is an abnormal mass of tissue as a result of neoplasia.

Study prompts further assessment of tomato extracts’ use in gastric cancer prevention

A new study shows that whole tomato extracts from two different Southern Italy cultivars inhibit gastric cancer cell growth and malignant features, paving the way for future studies aimed at implementing lifestyle habits not only for prevention but potentially as a support to conventional therapies.

15 May 2017

FDA approves new drug and chemotherapy combination for treatment of adult patients with AML

The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have a specific genetic mutation called FLT3, in combination with chemotherapy.

28 Apr 2017

Scientists develop new tool to analyse single-cell RNA data in pre-malignant blood cancers

Wellcome Trust Sanger Institute scientists and their collaborators have developed a new analysis tool that was able to show, for the first time, which genes were expressed by individual cells in different genetic versions of a benign blood cancer.

29 Mar 2017

Common drug for autoimmune disease may increase risk of myeloid neoplasms

Mayo Clinic researchers have found that azathioprine, a drug commonly used to treat autoimmune disease, may increase the risk of myeloid neoplasms.

3 Feb 2017

Study evaluates long-term safety of infants after maternal MRI exposure

In an analysis that included more than 1.4 million births, exposure to magnetic resonance imaging (MRI) during the first trimester of pregnancy compared with nonexposure was not associated with increased risk of harm to the fetus or in early childhood, although gadolinium MRI at any time during pregnancy was associated with an increased risk of a broad set of rheumatological, inflammatory, or skin conditions and, possibly, for stillbirth or neonatal death, according to a study appearing in the September 6 issue of JAMA.

6 Sep 2016

Study finds racial, ethnic disparities in utilization rate and health outcomes after TKR surgery

Minority populations have lower rates of total knee replacement (TKR) utilization but higher rates of adverse health outcomes associated with the procedure, according to a new study appearing in today's issue of the Journal of Bone and Joint Surgery.

4 Aug 2016

Researchers find oldest evidence of cancer in 1.7 million-year-old fossil

An international team of researchers led by scientists from the University of the Witwatersrand's Evolutionary Studies Institute and the South African Centre for Excellence in PalaeoSciences today announced in two papers, published in the South African Journal of Science, the discovery of the most ancient evidence for cancer and bony tumours yet described in the human fossil record.

28 Jul 2016

CNIO study shows proinflammatory molecule IL-17A can be key factor in development of NASH and HCC

Non-alcoholic steatohepatitis (NASH) is a serious hepatic condition that precedes hepatocellular carcinoma (HCC) and is currently untreatable.

12 Jul 2016

New method helps quantify HSATII RNA in blood serum of pancreatic cancer patients

Pancreatic ductal adenocarcinoma is one of the most aggressive and deadliest forms of cancer. Treatment options are limited because symptoms typically do not appear until the disease is advanced and complete surgical resection of tumors is not possible.

3 Jun 2016

International panel reclassifies a type of thyroid tumor to reduce cancer overdiagnosis

Led by researchers at the University of Pittsburgh School of Medicine, an international panel of pathologists and clinicians has reclassified a type of thyroid cancer to reflect that it is noninvasive and has a low risk of recurrence. The name change, described today in JAMA Oncology, is expected to reduce the psychological and medical consequences of a cancer diagnosis, potentially affecting thousands of people worldwide.

16 Apr 2016

Multimodal MRI recommended to prevent brain mass misdiagnosis

T2*-weighted gradient recalled echo or susceptibility-weighted imaging sequences should be performed during the diagnosis of brain masses to rule out pseudotumoural presentation of cerebral amyloid angiopathy-related inflammation, say researchers.

12 Feb 2016

Common mortality causes prevail in epilepsy patients

A prospective, community-based study confirms that patients with epilepsy usually die of the same causes as other people.

19 Jan 2016

Daiichi Sankyo, Plexxikon’s Phase 1 trial shows PLX3397 induced prolonged tumor regression in TGCT patients

Daiichi Sankyo Europe and Plexxikon Inc., a member of the Daiichi Sankyo Group, announced today that The New England Journal of Medicine published clinical trial results demonstrating that the investigational drug, PLX3397, an oral targeted CSF-1R inhibitor, induced prolonged tumor regressions in most patients with tenosynovial giant cell tumor, a rare, locally aggressive neoplasm of the joint or tendon sheath.

31 Jul 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

CTI BioPharma Corp. and Baxter International's Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill.

30 May 2015

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months.

29 May 2015

No evidence for cancer risk with growth hormone therapy

There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.

1 May 2015

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill).

From Baxter International Inc. 22 Apr 2015

VolitionRx's NuQ blood-based diagnostic platform demonstrates promising results in clinical study

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that it has completed a blinded clinical study demonstrating that its NuQ® blood-based diagnostic platform is able to accurately detect 84% of early, surgically-treatable pancreatic cancers at high 92% specificity.

8 Jan 2015

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

GEP-NETs stands for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). This is a type of rare cancer that is increasing in incidence and prevalence – more on this later.

22 Oct 2014